查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
北美的翼狀胬肉治療藥市場 - 產業趨勢和至2029年的預測
市場調查報告書
商品編碼
1100117

北美的翼狀胬肉治療藥市場 - 產業趨勢和至2029年的預測

NA Pterygium Drug Market - Industry Trends and Forecast to 2029
出版日期: | 出版商: Data Bridge Market Research | 英文 185 Pages | 商品交期: 請詢問到貨日

價格

北美的翼状胬肉治療藥的市場規模，預計2022年～2029年的預測期間以5.8％的年複合成長率擴大。

本報告提供北美的翼状胬肉治療藥市場相關調查，市場概要，以及各疾病類型，各階段，各治療，各製劑，各購買方法，各人口類型，各終端用戶，各流通管道，各地區的趨勢，及加入此市場的主要企業的簡介等資訊。

目錄

第1章 簡介

第2章 北美的翼状胬肉治療藥市場:市場區隔

第3章 摘要整理

第4章 重要考察

第5章 流行病學

第6章 開發平台分析

第7章 北美的翼状胬肉治療藥市場:法規

  • 美國的法規
  • 歐洲的法規
  • 中國的法規
  • 印度的法規
  • 這個架構相關的法律

第8章 市場概要

  • 促進因素
  • 阻礙因素
  • 機會
  • 課題

第9章 北美的翼状胬肉治療藥市場，各疾病類型

  • 概要
  • 進行性翼状胬肉
  • 萎縮性翼状胬肉

第10章 北美的翼状胬肉治療藥市場，各階段

  • 概要
  • 第2階段
  • 第3階段
  • 第1階段
  • 第4階段

第11章 北美的翼状胬肉治療藥市場，各治療

  • 概要
  • 人工淚液/局部潤滑劑
  • 類固醇眼科用藥

第12章 北美的翼状胬肉的藥物市場，各製劑

  • 概要
  • 眼科用藥
  • 軟膏
  • 其他

第13章 北美的翼状胬肉治療藥市場，各購買方法

  • 概要
  • 處方
  • 商店(OTC)

第14章 北美的翼状胬肉治療藥市場，各人口類型

  • 概要
  • 老年人
  • 成人

第15章 北美的翼状胬肉的藥物市場，各終端用戶

  • 概要
  • 醫院
  • 專門診所
  • 醫療保健
  • 其他

第16章 北美的翼状胬肉的藥物市場，各流通管道

  • 概要
  • 零售藥局
  • 院內藥局
  • 線上藥局
  • 其他

第17章 北美的翼状胬肉治療藥市場，各地區

  • 北美
    • 美國
    • 墨西哥
    • 加拿大

第18章 北美的翼状胬肉治療藥市場:企業形勢

  • 企業佔有率分析:北美

第19章 SWOT分析

第20章 企業簡介

  • ALCON
  • ABBVIE INC.
  • BAUSCH & LOMB INCORPORATED
  • JOHNSON & JOHNSON SERVICES, INC.
  • BAYER AG
  • NOVARTIS AG
  • SANTEN PHARMACEUTICAL CO., LTD.
  • AKORN OPERATING COMPANY LLC
  • AMNEAL PHARMACEUTICALS LLC.
  • EYERIS VISIONCARE PVT. LTD.
  • MAYA BIOTECH PRIVATE LIMITED
  • OASIS MEDICAL
  • PRESTIGE CONSUMER HEALTHCARE INC.
  • SAGER PHARMA
  • SIMILASAN CORPORATION
  • SPECTRA VISION CARE
  • SYLENTIS
  • THEA LABORATORIES
  • WELLONA PHARMA
  • ZYDUS GROUP

第21章 問卷調查

第22章 相關報告

The North America pterygium drug market is projected to register a substantial CAGR of 5.8% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.

Market Segmentation:

North America Pterygium Drug Market, By Type (Progressive Pterygium and Atrophic Pterygium), Stages (Stage 2, Stage 3, Stage 1, Stage 4), Treatment (Artificial Tears/Topical Lubricants and Steroid Eye Drops.), Formulation (Eye Drops, Eye Ointments, Others), Mode of Purchase (Prescription and Over the Counter (OTC)), Population Type (Geriatric and Adults), End-User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2029

Some of the major factors contributing to the growth of the North America pterygium drug market are:

Increase in healthcare awareness to reduce the risk of eye illnesses

Rising geriatric population

Market Players:

Some of the major players operating in the North America pterygium drug market are:

Johnson & Johnson Services, Inc.

Novartis AG

Akorn Operating Company LLC

Bausch & Lomb Incorporated

AbbVie Inc.

Prestige Consumer Healthcare Inc.

Sylentis

Bayer AG

Zydus Group

Amneal Pharmaceuticals LLC

OASIS Medical

Alcon

Santen Pharmaceutical Co.

TABLE OF CONTENTS

1 INTRODUCTION 37

  • 1.1 OBJECTIVES OF THE STUDY 37
  • 1.2 MARKET DEFINITION 37
  • 1.3 OVERVIEW OF NORTH AMERICA PTERYGIUM DRUG MARKET 37
  • 1.4 CURRENCY AND PRICING 39
  • 1.5 LIMITATIONS 39
  • 1.6 MARKETS COVERED 39

2 NORTH AMERICA PTERYGIUM DRUG MARKET: SEGMENTATION 43

  • 2.1 MARKETS COVERED 43
  • 2.2 GEOGRAPHICAL SCOPE 44
  • 2.3 YEARS CONSIDERED FOR THE STUDY 45
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 46
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 49
  • 2.6 MULTIVARIATE MODELLING 50
  • 2.7 CLASS SEGMENT LIFELINE CURVE 50
  • 2.8 DBMR MARKET POSITION GRID 51
  • 2.9 VENDOR SHARE ANALYSIS 52
  • 2.10 MARKET END USER COVERAGE GRID 53
  • 2.11 SECONDARY SOURCES 54

3 EXECUTIVE SUMMARY 55

4 PREMIUM INSIGHTS 59

  • 4.1 PESTEL'S MODEL 60
  • 4.2 PORTER'S 5 FORCES 61
  • 4.3 NORTH AMERICA PTERYGIUM DRUG MARKET: NUMBER OF SURGERIES 62

5 EPIDEMIOLOGY 63

6 PIPELINE ANALYSIS 64

7 NORTH AMERICA PTERYGIUM DRUG MARKET: REGULATIONS 65

  • 7.1 REGULATION IN THE U.S. 65
  • 7.2 REGULATION IN EUROPE: 66
  • 7.3 REGULATIONS IN CHINA: 66
  • 7.4 REGULATIONS IN INDIA: 67
  • 7.5 RELEVANT ACTS FOR THIS FRAMEWORK: 67

 

8 MARKET OVERVIEW 68

  • 8.1 DRIVERS 70
    • 8.1.1 RISE IN INCIDENCES AND PREVALENCE OF OPHTHALMIC DISORDERS 70
    • 8.1.2 RISE IN GERIATRIC POPULATION 70
    • 8.1.3 INCREASE IN HEALTHCARE AWARENESS TO REDUCE THE RISK OF EYE ILLNESSES 71
  • 8.2 RESTRAINTS 72
    • 8.2.1 HIGH COST OF EYE TREATMENT AND MEDICATION 72
    • 8.2.2 SIDE EFFECTS OF STEROIDS EYE DROPS 72
  • 8.3 OPPORTUNITIES 73
    • 8.3.1 PROGRAMS AND INITIATIVES TO REDUCE THE BURDEN OF EYE DISEASES 73
    • 8.3.2 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME 73
    • 8.3.3 INCREASE IN RESEARCH AND DEVELOPMENT ACTIVITIES 74
  • 8.4 CHALLENGES 75
    • 8.4.1 STRINGENT RULES & REGULATIONS 75
    • 8.4.2 EXPOSURE TO ULTRAVIOLET RADIATIONS 76

9 NORTH AMERICA PTERYGIUM DRUG MARKET, BY DISEASE TYPE 77

  • 9.1 OVERVIEW 78
  • 9.2 PROGRESSIVE PTERYGIUM 81
  • 9.3 ATROPHIC PTERYGIUM 81

10 NORTH AMERICA PTERYGIUM DRUG MARKET, BY STAGES 83

  • 10.1 OVERVIEW 84
  • 10.2 STAGE 2 87
  • 10.3 STAGE 3 87
  • 10.4 STAGE 1 88
  • 10.5 STAGE 4 89

11 NORTH AMERICA PTERYGIUM DRUG MARKET, BY TREATMENT 90

  • 11.1 OVERVIEW 91
  • 11.2 ARTIFICIAL TEARS/TOPICAL LUBRICANTS 94
    • 11.2.1 DEMULCENT 95
    • 11.2.2 EMOLLIENTS 95
  • 11.3 STEROID EYE DROPS 95
    • 11.3.1 KETONE STEROIDS 96
      • 11.3.1.1 PREDNOSOLONE 97
      • 11.3.1.2 DEXAMETHASONE 97
      • 11.3.1.3 FLUROMETHOLONE 97
      • 11.3.1.4 OTHERS 97
    • 11.3.2 ESTER STEROID (LOTERPREDNOL) 97

12 NORTH AMERICA PTERYGIUM DRUG MARKET, BY FORMULATION 98

  • 12.1 OVERVIEW 99
  • 12.2 EYE DROPS 102
    • 12.2.1 EYE DROPS WITH PRESERVATIVES 102
    • 12.2.2 PRESERVATIVE-FREE EYE DROPS 102
  • 12.3 EYE OINTMENTS 103
  • 12.4 OTHERS 103

13 NORTH AMERICA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE 105

  • 13.1 OVERVIEW 106
  • 13.2 PRESCRIPTION 109
  • 13.3 OVER THE COUNTER (OTC) 109

14 NORTH AMERICA PTERYGIUM DRUG MARKET, BY POPULATION TYPE 111

  • 14.1 OVERVIEW 112
  • 14.2 GERIATRIC 115
  • 14.3 ADULTS 115

15 NORTH AMERICA PTERYGIUM DRUG MARKET, BY END USER 117

  • 15.1 OVERVIEW 118
  • 15.2 HOSPITALS 121
  • 15.3 SPECIALTY CLINICS 121
  • 15.4 HOME HEALTHCARE 122
  • 15.5 OTHERS 122

16 NORTH AMERICA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL 124

  • 16.1 OVERVIEW 125
  • 16.2 RETAIL PHARMACIES 128
  • 16.3 HOSPITAL PHARMACIES 128
  • 16.4 ONLINE PHARMACIES 129
  • 16.5 OTHERS 129

17 NORTH AMERICA PTERYGIUM DRUG MARKET, BY REGION 131

  • 17.1 NORTH AMERICA 132
    • 17.1.1 U.S. 140
    • 17.1.2 MEXICO 143
    • 17.1.3 CANADA 146

18 NORTH AMERICA PTERYGIUM DRUG MARKET: COMPANY LANDSCAPE 149

  • 18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 149

19 SWOT ANALYSIS 150

20 COMPANY PROFILES 151

  • 20.1 ALCON 151
    • 20.1.1 COMPANY SNAPSHOT 151
    • 20.1.2 RECENT FINANCIALS 151
    • 20.1.3 COMPANY SHARE ANALYSIS 152
    • 20.1.4 PRODUCT PORTFOLIO 152
    • 20.1.5 RECENT DEVELOPMENTS 153
  • 20.2 ABBVIE INC. 154
    • 20.2.1 COMPANY SNAPSHOT 154
    • 20.2.2 REVENUE ANALYSIS 154
    • 20.2.3 COMPANY SHARE ANALYSIS 155
    • 20.2.4 PRODUCT PORTFOLIO 155
    • 20.2.5 RECENT DEVELOPMENT 155
  • 20.3 BAUSCH & LOMB INCORPORATED 156
    • 20.3.1 COMPANY SNAPSHOT 156
    • 20.3.2 REVENUE ANALYSIS 156
    • 20.3.3 COMPANY SHARE ANALYSIS 157
    • 20.3.4 PRODUCT PORTFOLIO 157
    • 20.3.5 RECENT DEVELOPMENT 157
  • 20.4 JOHNSON & JOHNSON SERVICES, INC. 158
    • 20.4.1 COMPANY SNAPSHOT 158
    • 20.4.2 REVENUE ANALYSIS 158
    • 20.4.3 COMPANY SHARE ANALYSIS 159
    • 20.4.4 PRODUCT PORTFOLIO 159
    • 20.4.5 RECENT DEVELOPMENTS 159
  • 20.5 BAYER AG 160
    • 20.5.1 COMPANY SNAPSHOT 160
    • 20.5.2 REVENUE ANALYSIS 160
    • 20.5.3 COMPANY SHARE ANALYSIS 161
    • 20.5.4 PRODUCT PORTFOLIO 161
    • 20.5.5 RECENT DEVELOPMENTS 161
  • 20.6 NOVARTIS AG 162
    • 20.6.1 COMPANY SNAPSHOT 162
    • 20.6.2 REVENUE ANALYSIS 162
    • 20.6.3 PRODUCT PORTFOLIO 163
    • 20.6.4 RECENT DEVELOPMENTS 163

 

  • 20.7 SANTEN PHARMACEUTICAL CO., LTD. 164
    • 20.7.1 COMPANY SNAPSHOT 164
    • 20.7.2 RECENT FINANCIALS 164
    • 20.7.3 PRODUCT PORTFOLIO 165
    • 20.7.4 RECENT DEVELOPMENT 165
  • 20.8 AKORN OPERATING COMPANY LLC 166
    • 20.8.1 COMPANY SNAPSHOT 166
    • 20.8.2 PRODUCT PORTFOLIO 166
    • 20.8.3 RECENT DEVELOPMENT 166
  • 20.9 AMNEAL PHARMACEUTICALS LLC. 167
    • 20.9.1 COMPANY SNAPSHOT 167
    • 20.9.2 REVENUE ANALYSIS 167
    • 20.9.3 PRODUCT PORTFOLIO 168
    • 20.9.4 RECENT DEVELOPMENTS 168
  • 20.10 EYERIS VISIONCARE PVT. LTD. 169
    • 20.10.1 COMPANY SNAPSHOT 169
    • 20.10.2 PRODUCT PORTFOLIO 169
    • 20.10.3 RECENT DEVELOPMENTS 169
  • 20.11 MAYA BIOTECH PRIVATE LIMITED 170
    • 20.11.1 COMPANY SNAPSHOT 170
    • 20.11.2 PRODUCT PORTFOLIO 170
    • 20.11.3 RECENT DEVELOPMENTS 170
  • 20.12 OASIS MEDICAL 171
    • 20.12.1 COMPANY SNAPSHOT 171
    • 20.12.2 PRODUCT PORTFOLIO 171
    • 20.12.3 RECENT DEVELOPMENTS 171
  • 20.13 PRESTIGE CONSUMER HEALTHCARE INC. 172
    • 20.13.1 COMPANY SNAPSHOT 172
    • 20.13.2 REVENUE ANALYSIS 172
    • 20.13.3 PRODUCT PORTFOLIO 173
    • 20.13.4 RECENT DEVELOPMENT 173
  • 20.14 SAGER PHARMA 174
    • 20.14.1 COMPANY SNAPSHOT 174
    • 20.14.2 PRODUCT PORTFOLIO 174
    • 20.14.3 RECENT DEVELOPMENTS 174
  • 20.15 SIMILASAN CORPORATION 175
    • 20.15.1 COMPANY SNAPSHOT 175
    • 20.15.2 PRODUCT PORTFOLIO 175
    • 20.15.3 RECENT DEVELOPMENTS 175

 

  • 20.16 SPECTRA VISION CARE 176
    • 20.16.1 COMPANY SNAPSHOT 176
    • 20.16.2 PRODUCT PORTFOLIO 176
    • 20.16.3 RECENT DEVELOPMENTS 176
  • 20.17 SYLENTIS 177
    • 20.17.1 COMPANY SNAPSHOT 177
    • 20.17.2 PRODUCT PORTFOLIO 177
    • 20.17.3 RECENT DEVELOPMENT 177
  • 20.18 THEA LABORATORIES 178
    • 20.18.1 COMPANY SNAPSHOT 178
    • 20.18.2 PRODUCT PORTFOLIO 178
    • 20.18.3 RECENT DEVELOPMENTS 178
  • 20.19 WELLONA PHARMA 179
    • 20.19.1 COMPANY SNAPSHOT 179
    • 20.19.2 PRODUCT PORTFOLIO 179
    • 20.19.3 RECENT DEVELOPMENTS 179
  • 20.20 ZYDUS GROUP 180
    • 20.20.1 COMPANY SNAPSHOT 180
    • 20.20.2 REVENUE ANALYSIS 180
    • 20.20.3 PRODUCT PORTFOLIO 181
    • 20.20.4 RECENT DEVELOPMENTS 181

21 QUESTIONNAIRE 182

22 RELATED REPORTS 185

LIST OF TABLES

  • TABLE 1 NORTH AMERICA PTERYGIUM DRUG MARKET, PIPELINE ANALYSIS 43
  • TABLE 2 NORTH AMERICA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION) 59
  • TABLE 3 NORTH AMERICA PROGRESSIVE PTERYGIUM IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 60
  • TABLE 4 NORTH AMERICA ATROPHIC PTERYGIUM IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 61
  • TABLE 5 NORTH AMERICA PTERYGIUM DRUG MARKET , BY STAGES, 2020-2029 (USD MILLION) 65
  • TABLE 6 NORTH AMERICA STAGE 2 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 66
  • TABLE 7 NORTH AMERICA STAGE 3 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 67
  • TABLE 8 NORTH AMERICA STAGE 1 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 67
  • TABLE 9 NORTH AMERICA STAGE 4 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 68
  • TABLE 10 NORTH AMERICA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 72
  • TABLE 11 NORTH AMERICA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 73
  • TABLE 12 NORTH AMERICA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION) 74
  • TABLE 13 NORTH AMERICA STEROID EYE DROPS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 75
  • TABLE 14 NORTH AMERICA STEROID EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION) 75
  • TABLE 15 NORTH AMERICA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION) 75
  • TABLE 16 NORTH AMERICA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 80
  • TABLE 17 NORTH AMERICA EYE DROPS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 81
  • TABLE 18 NORTH AMERICA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 81
  • TABLE 19 NORTH AMERICA EYE OINTMENTS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 82
  • TABLE 20 NORTH AMERICA OTHERS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 83
  • TABLE 21 NORTH AMERICA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION) 87
  • TABLE 22 NORTH AMERICA PRESCRIPTION IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 88
  • TABLE 23 NORTH AMERICA OVER THE COUNTER (OTC) IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 89
  • TABLE 24 NORTH AMERICA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 93
  • TABLE 25 NORTH AMERICA GERIATRICS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 94
  • TABLE 26 NORTH AMERICA ADULTS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 95
  • TABLE 27 NORTH AMERICA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION) 99
  • TABLE 28 NORTH AMERICA HOSPITALS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 100
  • TABLE 29 NORTH AMERICA SPECIALTY CLINICS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 101
  • TABLE 30 NORTH AMERICA HOME HEALTHCARE IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 101
  • TABLE 31 NORTH AMERICA OTHERS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 102
  • TABLE 32 NORTH AMERICA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 106
  • TABLE 33 NORTH AMERICA RETAIL PHARMACIES IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 107
  • TABLE 34 NORTH AMERICA HOSPITAL PHARMACIES IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 108
  • TABLE 35 NORTH AMERICA ONLINE PHARMACIES IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 108
  • TABLE 36 NORTH AMERICA OTHERS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION) 109
  • TABLE 37 NORTH AMERICA PTERYGIUM DRUG MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 116
  • TABLE 38 NORTH AMERICA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION) 116
  • TABLE 39 NORTH AMERICA PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION) 116
  • TABLE 40 NORTH AMERICA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 116
  • TABLE 41 NORTH AMERICA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION) 116
  • TABLE 42 NORTH AMERICA STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION) 117
  • TABLE 43 NORTH AMERICA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION) 117
  • TABLE 44 NORTH AMERICA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 117
  • TABLE 45 NORTH AMERICA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 117
  • TABLE 46 NORTH AMERICA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION) 118
  • TABLE 47 NORTH AMERICA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 118
  • TABLE 48 NORTH AMERICA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION) 118
  • TABLE 49 NORTH AMERICA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 118
  • TABLE 50 U.S. PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION) 119
  • TABLE 51 U.S. PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION) 119
  • TABLE 52 U.S. PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 119
  • TABLE 53 U.S. ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION) 119
  • TABLE 54 U.S. STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION) 120
  • TABLE 55 U.S. KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION) 120
  • TABLE 56 U.S. PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 120
  • TABLE 57 U.S. EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 120
  • TABLE 58 U.S. PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION) 121
  • TABLE 59 U.S. PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 121
  • TABLE 60 U.S. PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION) 121
  • TABLE 61 U.S. PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 121
  • TABLE 62 MEXICO PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION) 122
  • TABLE 63 MEXICO PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION) 122
  • TABLE 64 MEXICO PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 122
  • TABLE 65 MEXICO ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION) 122
  • TABLE 66 MEXICO STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION) 123
  • TABLE 67 MEXICO KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION) 123
  • TABLE 68 MEXICO PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 123
  • TABLE 69 MEXICO EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 123
  • TABLE 70 MEXICO PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION) 124
  • TABLE 71 MEXICO PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 124
  • TABLE 72 MEXICO PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION) 124
  • TABLE 73 MEXICO PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 124
  • TABLE 74 CANADA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION) 125
  • TABLE 75 CANADA PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION) 125
  • TABLE 76 CANADA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 125
  • TABLE 77 CANADA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION) 125
  • TABLE 78 CANADA STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION) 126
  • TABLE 79 CANADA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION) 126
  • TABLE 80 CANADA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 126
  • TABLE 81 CANADA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 126
  • TABLE 82 CANADA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION) 127
  • TABLE 83 CANADA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 127
  • TABLE 84 CANADA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION) 127
  • TABLE 85 CANADA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 127

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA PTERYGIUM DRUG MARKET: SEGMENTATION 21
  • FIGURE 2 NORTH AMERICA PTERYGIUM DRUG MARKET: DATA TRIANGULATION 24
  • FIGURE 3 NORTH AMERICA PTERYGIUM DRUG MARKET: DROC ANALYSIS 25
  • FIGURE 4 NORTH AMERICA PTERYGIUM DRUG MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 26
  • FIGURE 5 NORTH AMERICA PTERYGIUM DRUG MARKET: COMPANY RESEARCH ANALYSIS 26
  • FIGURE 6 NORTH AMERICA PTERYGIUM DRUG MARKET: INTERVIEW DEMOGRAPHICS 27
  • FIGURE 7 NORTH AMERICA PTERYGIUM DRUG MARKET: DBMR POSITION GRID 29
  • FIGURE 8 NORTH AMERICA PTERYGIUM DRUG MARKET: VENDOR SHARE ANALYSIS 30
  • FIGURE 9 NORTH AMERICA PTERYGIUM DRUG MARKET: END USER COVERAGE GRID 31
  • FIGURE 10 NORTH AMERICA PTERYGIUM DRUG MARKET: SEGMENTATION 35
  • FIGURE 11 ASIA-PACIFIC IS ANTICIPATED TO DOMINATE THE PTERYGIUM DRUG MARKET AND GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029 36
  • FIGURE 12 INCREASING PREVALENCE OF OPHTHALMIC DISORDERS AND RISE IN GERIATRIC POPULATION ARE EXPECTED TO DRIVE THE NORTH AMERICA PTERYGIUM DRUG MARKET FROM 2022 TO 2029 37
  • FIGURE 13 PROGRESSIVE PTERYGIUM SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE NORTH AMERICA PTERYGIUM DRUG MARKET FROM 2022 & 2029 37
  • FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA PTERYGIUM DRUG MARKET 47
  • FIGURE 15 AGEING POPULATION IN THE WORLD (IN MILLIONS) 49
  • FIGURE 16 NORTH AMERICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE, 2021 56
  • FIGURE 17 NORTH AMERICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION) 57
  • FIGURE 18 NORTH AMERICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE, CAGR (2022-2029) 57
  • FIGURE 19 NORTH AMERICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE, LIFELINE CURVE 58
  • FIGURE 20 NORTH AMERICA PTERYGIUM DRUG MARKET: BY STAGES, 2021 62
  • FIGURE 21 NORTH AMERICA PTERYGIUM DRUG MARKET: BY STAGES, 2022-2029 (USD MILLION) 63
  • FIGURE 22 NORTH AMERICA PTERYGIUM DRUG MARKET: BY STAGES, CAGR (2022-2029) 63
  • FIGURE 23 NORTH AMERICA PTERYGIUM DRUG MARKET: BY STAGES, LIFELINE CURVE 64
  • FIGURE 24 NORTH AMERICA PTERYGIUM DRUG MARKET: BY TREATMENT, 2021 69
  • FIGURE 25 NORTH AMERICA PTERYGIUM DRUG MARKET: BY TREATMENT, 2022-2029 (USD MILLION) 70
  • FIGURE 26 NORTH AMERICA PTERYGIUM DRUG MARKET: BY TREATMENT, CAGR (2022-2029) 70
  • FIGURE 27 NORTH AMERICA PTERYGIUM DRUG MARKET: BY TREATMENT, LIFELINE CURVE 71
  • FIGURE 28 NORTH AMERICA PTERYGIUM DRUG MARKET: BY FORMULATION, 2021 77
  • FIGURE 29 NORTH AMERICA PTERYGIUM DRUG MARKET: BY FORMULATION, 2022-2029 (USD MILLION) 78
  • FIGURE 30 NORTH AMERICA PTERYGIUM DRUG MARKET: BY FORMULATION, CAGR (2022-2029) 78
  • FIGURE 31 NORTH AMERICA PTERYGIUM DRUG MARKET: BY FORMULATION, LIFELINE CURVE 79
  • FIGURE 32 NORTH AMERICA PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, 2021 84
  • FIGURE 33 NORTH AMERICA PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION) 85
  • FIGURE 34 NORTH AMERICA PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, CAGR (2022-2029) 85
  • FIGURE 35 NORTH AMERICA PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, LIFELINE CURVE 86
  • FIGURE 36 NORTH AMERICA PTERYGIUM DRUG MARKET: BY POPULATION TYPE, 2021 90
  • FIGURE 37 NORTH AMERICA PTERYGIUM DRUG MARKET: BY POPULATION TYPE, 2022-2029 (USD MILLION) 91
  • FIGURE 38 NORTH AMERICA PTERYGIUM DRUG MARKET: BY POPULATION TYPE, CAGR (2022-2029) 91
  • FIGURE 39 NORTH AMERICA PTERYGIUM DRUG MARKET: BY POPULATION TYPE, LIFELINE CURVE 92
  • FIGURE 40 NORTH AMERICA PTERYGIUM DRUG MARKET: BY END USER, 2021 96
  • FIGURE 41 NORTH AMERICA PTERYGIUM DRUG MARKET: BY END USER, 2022-2029 (USD MILLION) 97
  • FIGURE 42 NORTH AMERICA PTERYGIUM DRUG MARKET: BY END USER, CAGR (2022-2029) 97
  • FIGURE 43 NORTH AMERICA PTERYGIUM DRUG MARKET: BY END USER, LIFELINE CURVE 98
  • FIGURE 44 NORTH AMERICA PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, 2021 103
  • FIGURE 45 NORTH AMERICA PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 104
  • FIGURE 46 NORTH AMERICA PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 104
  • FIGURE 47 NORTH AMERICA PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 105
  • FIGURE 48 NORTH AMERICA PTERYGIUM DRUG MARKET: SNAPSHOT (2021) 111
  • FIGURE 49 NORTH AMERICA PTERYGIUM DRUG MARKET: BY COUNTRY (2021) 113
  • FIGURE 50 NORTH AMERICA PTERYGIUM DRUG MARKET: BY COUNTRY (2022 & 2029) 113
  • FIGURE 51 NORTH AMERICA PTERYGIUM DRUG MARKET: BY COUNTRY (2021 & 2029) 114
  • FIGURE 52 NORTH AMERICA PTERYGIUM DRUG MARKET: BY DISEASE TYPE (2022-2029) 114
  • FIGURE 53 NORTH AMERICA PTERYGIUM DRUG MARKET: COMPANY SHARE 2021 (%) 127